menu
    • menu

    Company profile for Radiance Biopharma

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Radiance Biopharma is committed to developing next-generation Antibody Drug Conjugates (ADCs) to address cancer and other unmet medical needs. Our experienced team, comprising industry veterans from large pharmaceutical and biotech sectors, is dedicated to transforming patient care. Our innovative pipeline includes RB-164, a 'First-in-class' ADC targeting ROR-1; RB-201, a fully human bispecific ADC targeting HER2 and TROP-2; a...
    Radiance Biopharma is committed to developing next-generation Antibody Drug Conjugates (ADCs) to address cancer and other unmet medical needs. Our experienced team, comprising industry veterans from large pharmaceutical and biotech sectors, is dedicated to transforming patient care. Our innovative pipeline includes RB-164, a 'First-in-class' ADC targeting ROR-1; RB-201, a fully human bispecific ADC targeting HER2 and TROP-2; and RB-203, a proprietary monoclonal antibody against membrane Hsp70. Through these advancements, Radiance Biopharma aims to improve outcomes for patients worldwide.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Radiance BiopharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Boston Place, Ste. 2600 Boston, MA 02108
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://radiancebio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    China-based Novatim notches New Deal with Another US biotech
    China-based Novatim notches New Deal with Another US biotech

    03 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/03/3144055/0/en/Radiance-Biopharma-Signs-Exclusive-License-For-First-In-Class-c-Met-EGFR-Targeted-Nano-Antibody-ADC.html

    GLOBENEWSWIRE
    03 Sep 2025
    Share Share
    Radiance Begins Phase 1 Trial of ROR-1 ADC for Cancer
    Radiance Begins Phase 1 Trial of ROR-1 ADC for Cancer

    15 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/15/3062176/0/en/Radiance-Announces-First-Patient-Dosing-in-Phase-1-Clinical-Trial-of-its-Next-Generation-ROR-1-Targeted-ADC-for-Hematologic-and-Solid-Malignancies.html

    GLOBENEWSWIRE
    15 Apr 2025
    Share Share
    Radiance gets FDA clearance for RB-164 Phase 1 trial for cancers
    Radiance gets FDA clearance for RB-164 Phase 1 trial for cancers

    01 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/01/3053574/0/en/REPEAT-Radiance-Announces-FDA-Clearance-of-IND-Application-for-a-Phase-1-Clinical-Trial-of-RB-164-an-ROR-1-Targeted-ADC-for-Hematologic-and-Solid-Malignancies.html

    GLOBENEWSWIRE
    01 Apr 2025
    Share Share
    Radiance gets FDA clearance for RB-164 Phase 1 trial on cancer
    Radiance gets FDA clearance for RB-164 Phase 1 trial on cancer

    31 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/31/3052547/0/en/Radiance-Announces-FDA-Clearance-of-IND-Application-for-a-Phase-1-Clinical-Trial-of-RB-164-an-ROR-1-Targeted-ADC-for-Hematologic-and-Solid-Malignancies.html

    GLOBENEWSWIRE
    31 Mar 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search